Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Bioventus Inc (BVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: BVS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.75
1 Year Target Price $12.75
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 79.35% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 463.56M USD | Price to earnings Ratio 231 | 1Y Target Price 12.75 |
Price to earnings Ratio 231 | 1Y Target Price 12.75 | ||
Volume (30-day avg) 3 | Beta 0.83 | 52 Weeks Range 5.81 - 14.38 | Updated Date 08/12/2025 |
52 Weeks Range 5.81 - 14.38 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.21 | Actual 0.21 |
Profitability
Profit Margin 0.33% | Operating Margin (TTM) 12.45% |
Management Effectiveness
Return on Assets (TTM) 3.64% | Return on Equity (TTM) 1.39% |
Valuation
Trailing PE 231 | Forward PE 10.82 | Enterprise Value 771891659 | Price to Sales(TTM) 0.82 |
Enterprise Value 771891659 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 1.37 | Enterprise Value to EBITDA 8.88 | Shares Outstanding 66892300 | Shares Floating 34875640 |
Shares Outstanding 66892300 | Shares Floating 34875640 | ||
Percent Insiders 11.77 | Percent Institutions 72.45 |
Upturn AI SWOT
Bioventus Inc
Company Overview
History and Background
Bioventus Inc. was founded in 2012 as a spin-off from Smith & Nephew. It focuses on developing and marketing orthobiologic solutions to treat musculoskeletal conditions. The company has grown through organic expansion and acquisitions.
Core Business Areas
- Active Healing Therapies: This segment focuses on products that promote bone and tissue healing through electrical stimulation and ultrasound technologies.
- Surgical Solutions: This segment provides bone graft substitutes and other solutions used in surgical procedures to aid in bone regeneration and fracture repair.
- Pain Treatments: This segment focuses on non-surgical pain relief solutions using viscosupplementation and bracing.
Leadership and Structure
The CEO is Tony Bihl. The company operates with a functional organizational structure, dividing responsibilities across departments such as R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- DUROLANE: DUROLANE is a single-injection hyaluronic acid (HA) product used to treat osteoarthritis knee pain. Competitors include SYNVISC, ORTHOVISC and GEL-ONE. Data on market share is difficult to get a precise number, but Durolane is one of the key products in the OA knee market. Revenue associated with this product are substantial, comprising a significant portion of the company's pain treatment revenue.
- EXOGEN: EXOGEN is an ultrasound bone healing system used to treat non-union fractures and accelerate fracture healing. Competitors include OrthoFIX, Smith & Nephew and Zimmer Biomet. Exogen is a well known bone healing system within the space with substantial share but specific data is difficult to get precise values.
- OSTEOAMP: OSTEOAMP is a family of bone graft substitutes used in spinal fusion and other orthopedic procedures. Competitors include Medtronic, Stryker, and DePuy Synthes (Johnson & Johnson). The exact market share information or specific revenue of this product is unavailable
Market Dynamics
Industry Overview
The orthobiologics market is experiencing growth due to an aging population, increasing incidence of musculoskeletal disorders, and technological advancements. The market is competitive, with several large players and smaller innovative companies.
Positioning
Bioventus Inc. is positioned as a key player in the orthobiologics market, focusing on non-surgical and surgical solutions for bone and joint health. It leverages its proprietary technologies and established distribution network to maintain a competitive edge.
Total Addressable Market (TAM)
The global orthobiologics market is projected to reach over $11 billion by 2028. Bioventus is well-positioned to capture a portion of this expanding market through its diverse product portfolio and innovation.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Established distribution network
- Proprietary technologies
- Strong brand recognition in some product categories
Weaknesses
- Relatively smaller size compared to larger competitors
- Reliance on key products
- Historically inconsistent profitability
- High debt levels
Opportunities
- Expanding into new geographic markets
- Developing new products and indications
- Acquiring complementary technologies or businesses
- Increasing adoption of orthobiologics
Threats
- Intense competition
- Pricing pressures
- Regulatory changes
- Reimbursement challenges
- Product liability claims
Competitors and Market Share
Key Competitors
- SNY
- JNJ
- ZBH
Competitive Landscape
Bioventus faces stiff competition from larger, more established players. Its competitive advantages include its focus on orthobiologics and its proprietary technologies. Disadvantages include its smaller size and reliance on key products.
Major Acquisitions
Misonix, Inc.
- Year: 2021
- Acquisition Price (USD millions): 518
- Strategic Rationale: Expanded Bioventus' surgical solutions portfolio with ultrasonic medical devices used for wound debridement and bone grafting.
Growth Trajectory and Initiatives
Historical Growth: Bioventus has grown historically through product innovation, strategic acquisitions, and geographic expansion.
Future Projections: Analyst projections suggest continued growth driven by demand for orthobiologics and new product launches. Specific projections for financial figures are unavailable.
Recent Initiatives: Recent initiatives include focusing on cost management, product portfolio optimization, and expansion into international markets.
Summary
Bioventus is a key player in the orthobiologics market with a diverse product portfolio but faces strong competition. Its strength lies in proprietary technologies and established distribution. Areas to watch include managing debt and navigating reimbursement challenges. Continued innovation and market expansion will be crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bioventus Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2021-02-11 | President, CEO & Director Mr. Robert E. Claypoole | ||
Sector Healthcare | Industry Medical Devices | Full time employees 950 | Website https://www.bioventus.com |
Full time employees 950 | Website https://www.bioventus.com | ||
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.